Phase Ib Study of ZYG24002 Lotion for Safety, Tolerability, and Early Effectiveness in Adults With Mild to Moderate Seborrheic Dermatitis

What this Trial Is About

Researchers are evaluating the safety, tolerability, pharmacokinetics, and preliminary effectiveness of ZYG24002 Lotion in adults with mild to moderate seborrheic dermatitis, a skin condition characterized by redness and scaling. This Phase Ib trial involves adult patients with specific disease severity, aiming to better understand how different concentrations of the lotion behave in the body and their safety profiles. Participants are randomly assigned to receive one of four treatments 0.5%, 0.75%, or 1.0% concentrations of ZYG24002 Lotion or a placebo. The lotion is applied either once or twice daily for 28 consecutive days, depending on the assigned group. The study compares these different dosing schedules and concentrations to assess steady-state pharmacokinetics and tolerability. During the trial, participants will be monitored for serious and other adverse events, including local skin reactions and treatment discontinuations, throughout the study and for about one year after completion. Safety assessments include vital signs, lab tests, and electrocardiograms. Researchers will also evaluate treatment success rates, changes in skin redness and scaling, itch intensity, and quality of life at designated time points. Participants are expected to attend scheduled visits and complete assessments as instructed by the study team.

ZYG24002 Lotion to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Adult Patients With Mild to Moderate Seborrheic Dermatitis